MARC CANTILLON: Open Payments
NPI 1427037803 · LIVINGSTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$33,879 in 128 payments from 14 companies in 2025. Trend: 2023 $20,365 · 2024 $22,646 · 2025 $33,879
Speaker / faculty: $29,745Food & beverage: $3,024Travel & lodging: $1,091Education: $19
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 36 | $24,349 |
| ABBVIE INC. | 39 | $8,193 |
| Axsome Therapeutics, Inc. | 7 | $326 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $271 |
| Vanda Pharmaceuticals Inc. | 13 | $164 |
| Teva Pharmaceuticals USA, Inc. | 3 | $151 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Almatica Pharma LLC | 5 | $77 |
| Alkermes, Inc. | 3 | $55 |
| Neurocrine BioSciences, Inc. | 3 | $46 |
Products named: COBENFY, VRAYLAR, Auvelity, CAPLYTA, FANAPT, AUSTEDO XR, Qelbree, LOREEV XR.
Industry payments across NJ — which companies pay providers there.
